New publication: disease burden of myotonic dystrophy type 1

Nikoletta Nikolenko and Erik Landfeldt have published a new study on the impact of myotonic dystrophy type 1 (DM1) in the Journal of Neurology. They use a questionnaire-based method, the Individualized Neuromuscular Quality of Life Questionnaire (INQoL), to assess the burden of this condition on affected adults. The study provides further evidence of the wide range of domains affected in this multisystem disease. They are also able to show that INQoL scores correlate with the severity of the underlying genetic defect, linking CTG expansion with burden of illness. The study provides important baseline data for healthcare and for clinical research in myotonic dystrophy.

The full publication is available to read at the journal’s website here (open access)

Disease burden of myotonic dystrophy type 1
Landfeldt, E., Nikolenko, N., Jimenez-Moreno, C. Cumming, S., Monckton, D.G., Gorman, G., Turner, C.,Lochmüller, H.
J Neurol (2019).
https://doi.org/10.1007/s00415-019-09228-w

 

Abstract

Objective
The objective of this cross-sectional, observational study was to investigate the disease burden of myotonic dystrophy type 1 (DM1), a disabling muscle disorder.
Methods
Adults with DM1 were recruited as part of the PhenoDM1 study from Newcastle University (Newcastle upon Tyne, UK). Disease burden data were recorded through the Individualized Neuromuscular Quality of Life (INQoL) questionnaire. Results were examined by sex and clinical variables [e.g. the six-minute walk test (6MWT), the Mini Mental State Examination, and estimated progenitor and modal allele CTG repeat length].
Results
Our sample consisted of 60 patients with DM1 (mean age: 45 years; 45% female). Muscle weakness and fatigue constituted the two most common disease manifestations, reported by 93% and 90% of patients, respectively, followed by muscle locking (73%). Most patients (> 55%) reported feeling anxious/worried, depressed, frustrated, and/or having low confidence/self-esteem, 23% and 33% indicated substantial impairment of daily and leisure activities, respectively, and 47% did not work as a consequence of the disease. Estimated progenitor CTG length corrected by age correlated surprisingly well with INQoL scores. Differences by sex were generally minor.
Conclusion
We show that DM1 is associated with a substantial disease burden resulting in impairment across many different domains of patients’ lives, emphasizing the need for a holistic approach to medical management. Our results also show that the INQoL records relevant information about patients with DM1, but that further investigation of the psychometric properties of the scale is needed for meaningful interpretation of instrument scores.

inqol-dm1

Read next...

Neuromuscular junction and animal models

Meet the lab’s two new members

Our lab is growing! We are excited to introduce two new members who have joined the Lochmüller lab this winter. Daniel O'Neil Daniel holds a...
spendiff-agrin-nmj

New publication: Modulation of the Acetylcholine Receptor Clustering Pathway Improves Neuromuscular Junction Structure and Muscle Strength in a Mouse Model of CMS

Our new paper, spearheaded by our lab manager Dr Spendiff, is now available online at Frontiers Molecular Neuroscience. This project is a product of an...
JND_logo

Invitation to submit to special issues of the Journal of Neuromuscular Diseases

The Journal of Neuromuscular Diseases has two exciting special issues that are open for submission of NMD research papers. One is a special issue dedicated...
Journal of Neuromuscular Diseases

Latest edition of the Journal of Neuromuscular Diseases now online – Sep 2020

A new issue of the Journal of Neuromuscular Diseases has recently been released. Read it below: Journal of Neuromuscular Diseases: Volume 7, issue 4 *Hanns...
team-386673_1920

Meet the lab’s three new members

Our lab is growing! We are excited to introduce three new members who have joined the Lochmüller lab this summer. Kiran Polavarapu Dr Kiran Polavarapu...
treatabolome-presentations

Treatabolome presentations now online

Within the European Solve-RD project, we participate in work to create a "treatabolome" - a database of evidence for treatments for rare disorders linked to...